Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed.
Department of Medicine, Saint Agnes Hospital, 900 South Caton Avenue, Box 198, Baltimore, MD 21229, USA.
Mihail F
MF
Zilbermint
Adrian S
AS
Dobs
D000577:Amides / Q000494:pharmacology*; D000813:Anilides; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011944:Receptors, Androgen / Q000187:drug effects*
D000577:Amides; D000813:Anilides; D011944:Receptors, Androgen; C547106:ostarine; C034666:propionamide